RGBO ReGen Biologics Inc. featured news, full reports, and detailed charts
ReGen Biologics Inc. (RGBO/RGBO.OB) Wrap Up:
ReGen Biologics, Inc., a development stage company, engages in the design, development, manufacture, and marketing of minimally invasive human implants and medical devices for the repair and generation of soft tissue in humans primarily for orthopedic applications. Its proprietary collagen matrix technology includes applications in orthopedics, general surgery, spine, cardiovascular, and drug delivery. The company markets Menaflex, a collagen meniscus implant (CMI) device to facilitate growth of new tissue to reinforce the remaining meniscus in the European Union, Switzerland, Turkey, and the Republic of South Africa, as well as conducts pivotal multicenter clinical trials for CMI in the Uni...ReGen Biologics Inc. (RGBO:OTC Bulletin Board Market)
Snapshot of ReGen Biologics Inc. (RGBO)
|
OPEN
$0.31
|
PREVIOUS CLOSE
$0.50
|
|
|
DAY HIGH
$0.50
|
DAY LOW
$0.31
|
|
|
52 WEEK HIGH
12/22/08 - $5.90
|
52 WEEK LOW
11/13/09 - $0.30
|
|
|
MARKET CAP
4.8M
|
AVERAGE VOLUME 3 mo
4.3K
|
|
|
DILUTED EPS TTM
$-2.66
|
SHARES OUTSTANDING
9.8M
|
|
|
RGBO Does Not Pay Dividends
|
P/E TTM
NM
|
|
| K = Thousands M = Millions B = Billions | ||
RGBO Top Compensated Officers
Executives, Board Directors
Key developments for ReGen Biologics Inc. (RGBO)
On 11/16/2009, ReGen Biologics Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
ReGen Biologics Inc. said that it has entered into a bridge financing agreement for up to $3 million aggregate principal amount of secured convertible notes and closed on the first tranche of the agreement with one of its principal investors. In the first closing under the bridge financing, the company said that it received $250,000 in immediately available funds and initial commitments for $1.5 million to be provided to the company in increments to be established with the investors.
ReGen Biologics Inc. announced that effective October 2, 2009 and in connection with the company's personnel reductions in order to reduce its cash requirements, Brion D. Umidi, Senior Vice President and Chief Financial Officer, was terminated under his employment agreement with the company. The company expects to retain Mr. Umidi as a consultant to the company and for him to continue to be the company's principal financial officer.
RGBO Competitors
| Company | Last | Change |
| Exactech Inc | $16.16 USD | -0.01 |
| MiMedx Group Inc | $0.70 USD | -0.02 |
| Smith and Nephew | 574.00 GBX | 0.00 |
| Wright Medical Group Inc | $18.39 USD | +0.39 |
| Market data is delayed at least 20 minutes. | ||
Industry Analysis
| Valuation | RGBO | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | 3.2x |
|
| Price/Book | NM | Not Meaningful |
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | NM | Not Meaningful |
|
RGBO |
||
RGBO transactions
| Type Date |
Target |
|
Private Placement
October 2, 2009 |
-- |